Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms BREC
- 22 Nov 2018 Results assessing association of PALB2 messenger RNA expression with platinum-docetaxel efficacy published in the Journal of Thoracic Oncology.
- 31 May 2013 Planned interim results (cut-off 15 October 2012; n=279) presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2013 Based on the negative results for PFS at the interim analysis, accrual has been closed according to the abstract presented at the 49th Annual Meeting of the American Society of Clinical Oncology.